Bioleaders Corporation (142760) - Net Assets

Latest as of December 2025: ₩30.57 Billion KRW ≈ $20.71 Million USD

Based on the latest financial reports, Bioleaders Corporation (142760) has net assets worth ₩30.57 Billion KRW (≈ $20.71 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩42.61 Billion ≈ $28.87 Million USD) and total liabilities (₩12.04 Billion ≈ $8.16 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 142760 tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩30.57 Billion
% of Total Assets	71.74%
Annual Growth Rate	18.59%
5-Year Change	-32.25%
10-Year Change	75.04%
Growth Volatility	74.04

Bioleaders Corporation - Net Assets Trend (2015–2025)

This chart illustrates how Bioleaders Corporation's net assets have evolved over time, based on quarterly financial data. See 142760 defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Bioleaders Corporation (2015–2025)

The table below shows the annual net assets of Bioleaders Corporation from 2015 to 2025. For live valuation and market cap data, see how much is Bioleaders Corporation worth.

Year	Net Assets	Change
2025-12-31	₩30.57 Billion ≈ $20.71 Million	-18.07%
2024-12-31	₩37.31 Billion ≈ $25.28 Million	+4.22%
2023-12-31	₩35.79 Billion ≈ $24.26 Million	+65.05%
2022-12-31	₩21.69 Billion ≈ $14.70 Million	-51.93%
2021-12-31	₩45.11 Billion ≈ $30.57 Million	+47.41%
2020-12-31	₩30.60 Billion ≈ $20.74 Million	+28.49%
2019-12-31	₩23.82 Billion ≈ $16.14 Million	+1.36%
2018-12-31	₩23.50 Billion ≈ $15.92 Million	-33.18%
2017-12-31	₩35.17 Billion ≈ $23.83 Million	+101.38%
2016-12-31	₩17.46 Billion ≈ $11.83 Million	+214.49%
2015-12-31	₩5.55 Billion ≈ $3.76 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Bioleaders Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 13401165843000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Other Components	₩201.36 Billion	658.78%
Total Equity	₩30.57 Billion	100.00%

Bioleaders Corporation Competitors by Market Cap

The table below lists competitors of Bioleaders Corporation ranked by their market capitalization.

Company	Market Cap
BR.SCH.ED.HLD.SP.ADR CL.A F:BSK0	$16.44 Million
Indbank Merchant Banking Services Limited NSE:INDBANK	$16.44 Million
Enzo Biochem Inc NYSE:ENZ	$16.44 Million
Genenta Science SpA ADR NASDAQ:GNTA	$16.45 Million
Royal Prima PT JK:PRIM	$16.43 Million
Carboclor BA:CARC	$16.43 Million
US Copper Corp V:USCU	$16.43 Million
Curis Inc NASDAQ:CRIS	$16.41 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Bioleaders Corporation's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 37,305,571,860 to 30,565,041,770, a change of -6,740,530,090 (-18.1%).
Net loss of 13,051,157,000 reduced equity.
Other factors increased equity by 6,310,626,910.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	₩-13.05 Billion	-42.7%
Other Changes	₩6.31 Billion	+20.65%
Total Change	₩-	-18.07%

Book Value vs Market Value Analysis

This analysis compares Bioleaders Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.79x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has increased from 0.50x to 0.79x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	₩1234.18	₩621.00	x
2017-12-31	₩1930.51	₩621.00	x
2018-12-31	₩1285.57	₩621.00	x
2019-12-31	₩1176.11	₩621.00	x
2020-12-31	₩1116.42	₩621.00	x
2021-12-31	₩1574.19	₩621.00	x
2022-12-31	₩689.60	₩621.00	x
2023-12-31	₩1022.12	₩621.00	x
2024-12-31	₩988.62	₩621.00	x
2025-12-31	₩782.64	₩621.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Bioleaders Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -42.70%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -116.36%
• Asset Turnover: 0.26x
• Equity Multiplier: 1.39x
Recent ROE (-42.70%) is above the historical average (-76.01%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2015	-335.69%	-1260.95%	0.15x	1.72x	₩-19.19 Billion
2016	-33.76%	-235.76%	0.12x	1.24x	₩-7.64 Billion
2017	-18.90%	-87.38%	0.20x	1.07x	₩-10.16 Billion
2018	-73.32%	-20.02%	0.56x	6.52x	₩-19.58 Billion
2019	-117.75%	-38.48%	0.49x	6.22x	₩-30.43 Billion
2020	-69.07%	-26.27%	0.42x	6.23x	₩-24.20 Billion
2021	-43.82%	-19.54%	0.54x	4.19x	₩-24.28 Billion
2022	-106.69%	-23.04%	0.68x	6.84x	₩-25.31 Billion
2023	24.28%	43.90%	0.37x	1.49x	₩4.71 Billion
2024	-18.75%	-44.75%	0.25x	1.67x	₩-10.72 Billion
2025	-42.70%	-116.36%	0.26x	1.39x	₩-16.11 Billion

Industry Comparison

This section compares Bioleaders Corporation's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $404,884,724,361
Average return on equity (ROE) among peers: -5.25%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Bioleaders Corporation (142760)	₩30.57 Billion	-335.69%	0.39x	$16.44 Million
ORIENTBIO Inc. (002630)	$44.21 Billion	0.00%	0.54x	$72.49 Million
Green Cross (005250)	$1.85 Trillion	1.30%	0.98x	$342.58 Million
Green Cross Holdings Preference Shares (005257)	$1.88 Trillion	-2.88%	0.99x	$3.26 Million
Pharmicell (005690)	$86.44 Billion	7.32%	0.15x	$579.46 Million
GeneOne Life Science Inc (011000)	$29.41 Billion	-40.45%	0.68x	$51.80 Million
HLB Co. Ltd (028300)	$18.60 Billion	0.00%	1.06x	$4.45 Billion
Daesung Microbiological Labs. Co. Ltd (036480)	$36.31 Billion	4.18%	0.71x	$16.87 Million
Seoulin Bioscience Co.Ltd (038070)	$45.30 Billion	4.03%	0.46x	$30.03 Million
Hyundai Bioscience Co. Ltd (048410)	$24.60 Billion	2.89%	0.76x	$598.77 Million
iNtRON Biotechnology Inc (048530)	$30.24 Billion	-28.88%	0.51x	$59.56 Million

About Bioleaders Corporation

KQ:142760 Korea Biotechnology

Market Cap

$16.44 Million

₩24.25 Billion KRW

Market Cap Rank

#25738 Global

#1876 in Korea

Share Price

₩621.00

Change (1 day)

-1.11%

52-Week Range

₩606.00 - ₩2170.00

All Time High

₩24990.00